Literature DB >> 18853337

Metabotropic glutamate receptor 2 and 3 gene expression in the human prefrontal cortex and mesencephalon in schizophrenia.

Subroto Ghose1, Jeremy M Crook, Cynthia L Bartus, Thomas G Sherman, Mary M Herman, Thomas M Hyde, Joel E Kleinman, Mayada Akil.   

Abstract

Group II metabotropic glutamate receptors (mGluR2 and mGluR3) are implicated in schizophrenia. We characterized mGluR2 and 3 mRNA in the human prefrontal cortex (PFC) and mesencephalon, and then compared cases with schizophrenia to matched controls. In the human brain, both receptors were expressed in the PFC and, unlike the rodent, in dopaminergic (DA) cell groups. In schizophrenia, we found significantly higher levels of mGluR2 mRNA in the PFC white matter. The expression of mGluR2, 3 in DA cells provide a mechanism for glutamate to modulate dopamine release in the human brain and this species-specific difference may be critical to understanding rodent models in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18853337      PMCID: PMC2749493          DOI: 10.1080/00207450802330702

Source DB:  PubMed          Journal:  Int J Neurosci        ISSN: 0020-7454            Impact factor:   2.292


  51 in total

1.  Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia.

Authors:  Michael F Egan; Richard E Straub; Terry E Goldberg; Imtiaz Yakub; Joseph H Callicott; Ahmad R Hariri; Venkata S Mattay; Alessandro Bertolino; Thomas M Hyde; Cynthia Shannon-Weickert; Mayada Akil; Jeremy Crook; Radha Krishna Vakkalanka; Rishi Balkissoon; Richard A Gibbs; Joel E Kleinman; Daniel R Weinberger
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-13       Impact factor: 11.205

2.  Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment.

Authors:  Jeffrey R Bishop; Vicki L Ellingrod; Jessica Moline; Del Miller
Journal:  Schizophr Res       Date:  2005-09-15       Impact factor: 4.939

3.  Alternative splicing of human metabotropic glutamate receptor 3.

Authors:  Leah J Sartorius; Guhan Nagappan; Barbara K Lipska; Bai Lu; Yoshitatsu Sei; Renee Ren-Patterson; Zhen Li; Daniel R Weinberger; Paul J Harrison
Journal:  J Neurochem       Date:  2006-01-17       Impact factor: 5.372

4.  Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats.

Authors:  B Moghaddam; B W Adams
Journal:  Science       Date:  1998-08-28       Impact factor: 47.728

5.  Metabotropic glutamate receptor 3 (GRM3) gene variation is not associated with schizophrenia or bipolar affective disorder in the German population.

Authors:  Sylvia Bort Martí; Sven Cichon; Peter Propping; Markus Nöthen
Journal:  Am J Med Genet       Date:  2002-01-08

6.  A case-control study of the relationship between the metabotropic glutamate receptor 3 gene and schizophrenia in the Chinese population.

Authors:  Qi Chen; Guang He; Qingying Chen; Shengnan Wu; Yifeng Xu; Guoyin Feng; Yucheng Li; Lijun Wang; Lin He
Journal:  Schizophr Res       Date:  2005-02-01       Impact factor: 4.939

7.  Heterogeneous targets of dopamine synapses in monkey prefrontal cortex demonstrated by serial section electron microscopy: a laminar analysis using the silver-enhanced diaminobenzidine sulfide (SEDS) immunolabeling technique.

Authors:  J F Smiley; P S Goldman-Rakic
Journal:  Cereb Cortex       Date:  1993 May-Jun       Impact factor: 5.357

8.  Glutamate transport, glutamine synthetase and phosphate-activated glutaminase in rat CNS white matter. A quantitative study.

Authors:  Bjørnar Hassel; Karen Astrid Boldingh; Cecilie Narvesen; Evy Grini Iversen; Knut Kristian Skrede
Journal:  J Neurochem       Date:  2003-10       Impact factor: 5.372

Review 9.  White matter changes in schizophrenia: evidence for myelin-related dysfunction.

Authors:  Kenneth L Davis; Daniel G Stewart; Joseph I Friedman; Monte Buchsbaum; Philip D Harvey; Patrick R Hof; Joseph Buxbaum; Vahram Haroutunian
Journal:  Arch Gen Psychiatry       Date:  2003-05

10.  No evidence for association between polymorphisms in GRM3 and schizophrenia.

Authors:  Nadine Norton; Hywel J Williams; Sarah Dwyer; Dobril Ivanov; Anna C Preece; Amy Gerrish; Nigel M Williams; Pamela Yerassimou; Stanley Zammit; Michael C O'Donovan; Michael J Owen
Journal:  BMC Psychiatry       Date:  2005-05-13       Impact factor: 3.630

View more
  17 in total

Review 1.  The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies.

Authors:  Wei Hu; Matthew L MacDonald; Daniel E Elswick; Robert A Sweet
Journal:  Ann N Y Acad Sci       Date:  2014-10-14       Impact factor: 5.691

2.  Metabotropic glutamate receptor 3 activation is required for long-term depression in medial prefrontal cortex and fear extinction.

Authors:  Adam G Walker; Cody J Wenthur; Zixiu Xiang; Jerri M Rook; Kyle A Emmitte; Colleen M Niswender; Craig W Lindsley; P Jeffrey Conn
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-12       Impact factor: 11.205

Review 3.  Positive allosteric modulators of metabotropic glutamate 2 receptors in schizophrenia treatment.

Authors:  Amr Ellaithy; Jason Younkin; Javier González-Maeso; Diomedes E Logothetis
Journal:  Trends Neurosci       Date:  2015-07-04       Impact factor: 13.837

4.  Elevated levels of kynurenic acid during gestation produce neurochemical, morphological, and cognitive deficits in adulthood: implications for schizophrenia.

Authors:  Michelle L Pershing; David M Bortz; Ana Pocivavsek; Peter J Fredericks; Christinna V Jørgensen; Sarah A Vunck; Benedetta Leuner; Robert Schwarcz; John P Bruno
Journal:  Neuropharmacology       Date:  2014-11-01       Impact factor: 5.250

5.  The mGluR2/3 agonist LY379268 reverses post-weaning social isolation-induced recognition memory deficits in the rat.

Authors:  Caitlin A Jones; Angus M Brown; Dorothee P Auer; Kevin C F Fone
Journal:  Psychopharmacology (Berl)       Date:  2010-07-07       Impact factor: 4.530

Review 6.  Group II metabotropic glutamate receptors and schizophrenia.

Authors:  José L Moreno; Stuart C Sealfon; Javier González-Maeso
Journal:  Cell Mol Life Sci       Date:  2009-08-26       Impact factor: 9.261

7.  Localization of NAAG-related gene expression deficits to the anterior hippocampus in schizophrenia.

Authors:  Subroto Ghose; Ronald Chin; Analysa Gallegos; Rosalinda Roberts; Joseph Coyle; Carol Tamminga
Journal:  Schizophr Res       Date:  2009-04-28       Impact factor: 4.939

8.  Differential expression of metabotropic glutamate receptors 2 and 3 in schizophrenia: a mechanism for antipsychotic drug action?

Authors:  Subroto Ghose; Kelly A Gleason; Bryan W Potts; Kelly Lewis-Amezcua; Carol A Tamminga
Journal:  Am J Psychiatry       Date:  2009-06-01       Impact factor: 18.112

Review 9.  Serotonergic hallucinogens as translational models relevant to schizophrenia.

Authors:  Adam L Halberstadt; Mark A Geyer
Journal:  Int J Neuropsychopharmacol       Date:  2013-08-13       Impact factor: 5.176

10.  Therapeutic potential of metabotropic glutamate receptor modulators.

Authors:  N Hovelsø; F Sotty; L P Montezinho; P S Pinheiro; K F Herrik; A Mørk
Journal:  Curr Neuropharmacol       Date:  2012-03       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.